Table 1.
Cohort (Dose-Level) |
Pt # |
Sex/ Age, y |
Diagnosis-status at alloHSCT |
Disease Risk | Donor type |
Conditioning Regimen |
Days from alloHSCT to Dec |
Chimerism at enrollment, % |
---|---|---|---|---|---|---|---|---|
1 (5 mg/m2) |
1 | M/62 | AML-PD | Ph+ AML | mMUD | BU/CY | 95 | 100 |
2 | F/59 | AML-PD | Prior MF, trisomy 8, FLT3-ITD + | MRD | BU/CY | 62 | Mixed | |
3 | M/37 | AML-CR1 | Monosomy 7 | MUD | BU/CY | 75 | 100 | |
4 | M/62 | AML-PD | Prior MDS, trisomy 19 | MUD | TBI/CY | 95 | Mixed | |
5 | M/57 | MDS | Trisomy 8, 5q- | MUD | BU/CY | 76 | 100 | |
6 | M/59 | AML-CR2 | t (8,21), CR2 | MUD | BU/CY | 77 | 100 | |
7 | M/42 | AML-CR1 | Del 12/ETV6 | mMUD | BU/CY | 115 | 100 | |
8 | M/52 | MDS | Del 5, Del 6 | MUD | BU/CY | 90 | 100 | |
9 | M/58 | AML-CR1 | Complex cytogenetics | MRD | BU/CY | 98 | 100 | |
2 (7.5 mg/m2) |
10 | F/68 | AML-CR1 | Complex cytogenetics | MRD | FLU/BU | 96 | 100 |
11 | F/65 | AML-CR1 | FLT 3-ITD + | MUD | TBI/CY | 96 | 100 | |
12 | F/45 | AML-CR1 | Therapy related AML | mMRD | BU/CY | 98 | 100 | |
13 | M/63 | AML-CR1 | Prior MDS | mMUD | BU/CY | 103 | 100 | |
3 (10 mg/m2) |
14 | M/21 | AML-CR1 | FLT3-ITD + | MUD | BU/CY | 97 | 100 |
15 | F/56 | AML-CR1 | Complex cytogenetics | MUD | BU/CY | 87 | 100 | |
16 | M/62 | MDS | High-grade MDS | MUD | BU/CY | 95 | 100 | |
17 | M/63 | AML-CR1 | Prior MDS | MRD | BU/CY | 102 | 100 | |
4 (15 mg/m2) |
18 | F/54 | AML-CR2 | CR2 | MRD | BU/CY | 95 | 100 |
19 | F/51 | AML-CR1 | MLL rearrangement | MUD | BU/CY | 82 | 100 | |
20 | M/57 | MDS | Del 7 | mMUD | BU/CY | 86 | 100 | |
21 | M/67 | AML-CR1 | Del 17p (p53) | MUD | FLU/BU | 74 | 100 | |
22 | M/66 | MDS | High-grade MDS | MRD | BU/CY | 100 | 100 |
AlloHSCT indicates allogeneic hematopoietic stem cell transplantation; AML, acute myelogenous leukemia; BU, busulfan; CR, complete remission; CY, cyclophosphamide; Dec, decitabine; Del, deletion; Flu, fludarabine; GVHD, graft-versus-host disease; MDS, melodysplastic syndrome; MF, myelofibrosis; mMRD, mismatched related donor; mMUD, mismatched unrelated donor; MRD, matched related donor; MUD, matched unrelated donor; PD, persistent disease; Ph, Philadelphia chromosome; Pt, patient; TBI, total body irradiation.